Revenue
2020
2021
2022
2023
2024
2025
Bausch & Lomb Corp (BLCO)
Price$18.04Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $5.10B | $4.79B | $4.15B | $3.77B | $3.77B | $3.41B |
| Research & development | $371.0M | $343.0M | $324.0M | $307.0M | $271.0M | $253.0M |
| Operating expenses | $4.99B | $4.63B | $4.02B | $3.56B | $3.44B | $3.15B |
| Operating income | $113.0M | $162.0M | $130.0M | $207.0M | $329.0M | $260.0M |
| Operating margin | 2.22% | 3.38% | 3.14% | 5.49% | 8.74% | 7.62% |
| EBITDA | $534.0M | $598.0M | $512.0M | $586.0M | $744.0M | $702.0M |
| EBITDA margin | 10.47% | 12.48% | 12.35% | 15.55% | 19.76% | 20.57% |
| Net income | −$360.0M | −$317.0M | −$260.0M | $6.0M | $182.0M | −$18.0M |
| Net profit margin | −7.06% | −6.62% | −6.27% | 0.16% | 4.83% | −0.53% |
| Basic EPSper basic share | -$1.02 | -$0.90 | -$0.74 | $0.02 | $0.52 | -$0.05 |
| Diluted EPSper diluted share | -$1.02 | -$0.90 | -$0.74 | $0.02 | $0.52 | -$0.05 |
Owners
Reported shareholders
0.98%of listed shares
ICAHN CARL C3.5M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
ICAHN CARL C | 0.98%3.5M shares |
OAKTREE CAPITAL MANAGEMENT LP | 0.96%3.44M shares |
DEUTSCHE BANK AG\ | 0.96%3.42M shares |
D. E. Shaw & Co., Inc. | 0.93%3.32M shares |
Davidson Kempner Capital Management LP | 0.88%3.16M shares |
GOLDENTREE ASSET MANAGEMENT LP | 0.75%2.66M shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 0.61%2.16M shares |
CASPIAN CAPITAL LP | 0.56%2M shares |
GLENVIEW CAPITAL MANAGEMENT, LLC | 0.54%1.92M shares |
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 0.38%1.36M shares |
CITADEL ADVISORS LLC | 0.28%987.73K shares |
SAUNDERS BRENT L | ≈0.27%978.39K shares |
CLARK ESTATES INC/NY | 0.25%881K shares |
MORGAN STANLEY | 0.20%703.35K shares |
Clearline Capital LP | 0.20%701.97K shares |
WHITEBOX ADVISORS LLC | 0.19%686.98K shares |
GordonMD Global Investments LP | 0.16%573.47K shares |
TUDOR INVESTMENT CORP ET AL | 0.15%532.03K shares |
UBS Group AG | 0.13%465.2K shares |
GOLDMAN SACHS GROUP INC | 0.12%420.19K shares |
Percentages use 357.06M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 6, 2026Form 4 | Bailey A Robert DEVP & Chief Legal Officer | BuyCommon Shares, No Par Value | 14.6K | $17.15 | $250.4K | 231.9K |
| Mar 6, 2026Form 4 | Eldessouky SamEVP and CFO | BuyCommon Shares, No Par Value | 4.0K | $17.13 | $68.5K | 403.1K |
| Mar 6, 2026Form 4 | SAUNDERS BRENT LCEO and Chairman of the Board | BuyCommon Shares, No Par Value | 14.7K | $17.14 | $252.0K | 966.6K |
| Mar 3, 2026Form 4 | Ross Thomas W. Sr.Director | BuyCommon Shares, No Par Value | 4.5K | $17.68 | $79.6K | 64.9K |
| Mar 2, 2026Form 4 | Alfonso EduardoDirector | BuyCommon Shares, No Par Value | 4.3K | $17.90 | $77.0K | 9.6K |
Community posts
Bausch + Lomb receives European clearance for SeeLyra surgical laser
Bausch + Lomb ($BLCO) received European CE marking for SeeLyra, a femtosecond laser platform used in the preparation stages of cataract, LASIK-flap and therapeutic corneal procedures. The system combines real-time imaging with a compact des ...
